Ultra-long-acting, self-administered HIV treatment for HIV and HIV/HBV co-infection
Official title: Development of an Ultra-Long-Acting, Self-Administered, Dolutegravir-Based Treatment Regimen for HIV-1 and HIV-HBV Co-infection
Funded at Exavir Therapeutics INC. · NIH-11254817 · Data updated 2026-11-12
A new, long-lasting HIV treatment regimen that you could self-administer and potentially reduce frequent clinic visits, with a focus on people living with HIV and HIV/HBV co-infection.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Exavir Therapeutics INC. NIH-funded |
| Lab location | 1 site (San Francisco, UNITED STATES) |
| Project start | August 4, 2026 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $998,034 |
| NIH project number | 1R44AI195119-01 |
| Project ID | NIH-11254817 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with HIV, including those co-infected with HIV and HBV, who may benefit from a self-administered, long-acting regimen.
✕Less likely to help
Patients who cannot self-administer injections or have contraindications to the proposed drug components may see limited or no benefit.
What this research studies
This grant funds development of a self-administered, ultra-long-acting dolutegravir-based regimen that aims to simplify treatment for people living with HIV, including those with HBV co-infection. Researchers plan to create low-volume injectable formulations that could be given at home or by non-clinical staff, potentially improving adherence and convenience. The work targets gaps in current long-acting options, such as the need for self-administration and better effectiveness against drug resistance. The project is designed to move from early development toward Phase II testing to evaluate safety, tolerability, and real-world usability.
Why it matters
Potential benefit: If successful, patients could experience easier, less frequent dosing and improved adherence, leading to better viral suppression and quality of life.
How similar studies have gone: Long-acting ARV approaches have shown promise, but self-administered, single-injection regimens for HIV/HBV co-infection remain under development.
Where this research is happening
-
Exavir Therapeutics INC.
San Francisco, United States Active
Researchers
- Principal investigator: Kearney, Brian — Exavir Therapeutics INC.
- Study coordinator: Kearney, Brian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.